Yazarlar : Levine JE, Logan BR, Wu J , et al

Yayın : Blood.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22383800

Konu : Kemik İliği Nakli

Literatür İçeriği :  

Abstract

Acute graft-versus-host disease (GVHD) is the primary limitation of allogeneic hematopoietic cell transplantation (HCT) and once it develops, there are no reliable diagnostic tests to predict treatment outcomes. We hypothesized that six previously validated diagnostic biomarkers of GVHD (IL2Rα, TNFR1, HGF, IL8, elafin, a skin-specific marker, and reg3α, a gastrointestinal tract-specific marker) could discriminate between therapy responsive and non-responsive patients and predict survival in patients receiving GVHD therapy. We measured GVHD biomarker concentrations from samples prospectively obtained at the initiation of treatment, day 14, and day 28, on a multicenter, randomized, four-arm phase II clinical trial for newly diagnosed acute GVHD. We found that at each of three time points, GVHD onset, two weeks into treatment, and four weeks into treatment, a six protein biomarker panel predicted for the important clinical outcomes of day 28 post-therapy non-response and mortality at day 180 from onset. GVHD biomarker panels can be used for early identification of patients at high or low risk for treatment non-responsiveness or death, and may provide opportunities for early intervention and improved survival following HCT. The study was registered in clinicaltrials.gov as NCT00224874.

Literatür Arşivi